logo-loader

Rubianna Resources AGM Presentation

Last updated: 18:00 23 Mar 2014 EDT, First published: 17:00 23 Mar 2014 EDT

no_picture_pai

Rubianna Resources AGM Presentation

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

20 minutes ago